References
- Dooley M, Goa KL. Capecitabine. Drugs 1999; 58: 69–76
- Keam, SJ, Chapman, TM, Figgitt, DP. Brivudin (bromovinyl deoxyuridine). Drugs 2004;64:2091–7; Discussion 2098–9.
- Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Cancer Res Clin Oncol 1994; 120: 545–9
- Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287: 791–9
- De Clercq E. (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Med Res Rev 2005; 25: 1–20
- Marston E, Leibundgut G, Kühne M, Rätz Bravo A, Hofer S, Ludwig C. Eine tödliche Arzneimittelinteraktion. Schweiz Med Forum 2006; 6: 350–2